MX2023004034A - Métodos de tratamiento de la dermatomiositis. - Google Patents

Métodos de tratamiento de la dermatomiositis.

Info

Publication number
MX2023004034A
MX2023004034A MX2023004034A MX2023004034A MX2023004034A MX 2023004034 A MX2023004034 A MX 2023004034A MX 2023004034 A MX2023004034 A MX 2023004034A MX 2023004034 A MX2023004034 A MX 2023004034A MX 2023004034 A MX2023004034 A MX 2023004034A
Authority
MX
Mexico
Prior art keywords
methods
dermatomyositis
treating
treating dermatomyositis
composition
Prior art date
Application number
MX2023004034A
Other languages
English (en)
Spanish (es)
Inventor
Paul P Tamburini
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2023004034A publication Critical patent/MX2023004034A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/20Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/28Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
MX2023004034A 2020-10-05 2021-10-05 Métodos de tratamiento de la dermatomiositis. MX2023004034A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063087577P 2020-10-05 2020-10-05
PCT/US2021/053540 WO2022076388A1 (en) 2020-10-05 2021-10-05 Methods of treating dermatomyositis

Publications (1)

Publication Number Publication Date
MX2023004034A true MX2023004034A (es) 2023-06-09

Family

ID=81126239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004034A MX2023004034A (es) 2020-10-05 2021-10-05 Métodos de tratamiento de la dermatomiositis.

Country Status (10)

Country Link
US (1) US20230357442A1 (enExample)
EP (1) EP4225372A4 (enExample)
JP (1) JP2023544409A (enExample)
KR (1) KR20230084210A (enExample)
CN (1) CN116472065A (enExample)
AU (1) AU2021358027A1 (enExample)
CA (1) CA3172994A1 (enExample)
IL (1) IL301713A (enExample)
MX (1) MX2023004034A (enExample)
WO (1) WO2022076388A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116313071B (zh) * 2023-01-16 2023-09-08 南方医科大学南方医院 一种预测初诊皮肌炎患者发生快速进展型间质性肺病的风险模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2794359A (en) * 1953-09-22 1957-06-04 Lyman Gun Sight Corp Automatic primer feed device
KR101850687B1 (ko) * 2010-04-21 2018-04-20 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
RS58503B1 (sr) * 2012-02-20 2019-04-30 Swedish Orphan Biovitrum Ab Publ Polipeptidi koji se vezuju za humani komplement c5
US10531135B2 (en) * 2016-01-04 2020-01-07 Telefonaktiebolaget Lm Ericsson (Publ) Network recording apparatus
CN111201246B (zh) * 2017-07-11 2023-10-27 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2020198062A1 (en) * 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
JP2024520421A (ja) * 2021-05-25 2024-05-24 アレクシオン ファーマシューティカルズ, インコーポレイテッド 腎臓活性融合タンパク質及びそれを使用する治療方法
CA3177998A1 (en) * 2021-08-20 2023-02-20 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor

Also Published As

Publication number Publication date
AU2021358027A1 (en) 2023-05-11
KR20230084210A (ko) 2023-06-12
WO2022076388A1 (en) 2022-04-14
US20230357442A1 (en) 2023-11-09
JP2023544409A (ja) 2023-10-23
EP4225372A1 (en) 2023-08-16
CA3172994A1 (en) 2022-04-14
IL301713A (en) 2023-05-01
EP4225372A4 (en) 2024-11-06
CN116472065A (zh) 2023-07-21

Similar Documents

Publication Publication Date Title
JOP20200309A1 (ar) أجسام مضادة لـ il-11
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
ZA202202363B (en) Antibodies against ilt2 and use thereof
MX392869B (es) Kit para el tratamiento o alivio de dolor en el sitio de incision despues de un procedimiento quirurgico
EP4338804A3 (en) Epinephrine spray formulations
CR20200088A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
SA523440622B1 (ar) أجسام مضادة
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
PH12022550130A1 (en) Enzyme inhibitors
MX2020011817A (es) Metodos para tratar el linfoma.
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
MX2021012977A (es) Tratamiento del cáncer con tg02.
PH12022551035A1 (en) Siglec-9 ecd fusion molecules and methods of use thereof
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MY199876A (en) Anti-pacap antibody
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
MX2024001211A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de tipos de cancer de sangre.
WO2018189661A3 (en) Methods and compounds for treating diabetes
MX2022004755A (es) Inyector intravitreo.
MX2022000811A (es) Inhibidores de enzimas.
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
MY200161A (en) Bacteria for targeting tumors and treating cancer
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
EA202090558A1 (ru) Схемы лечения